Table 2.
pFADD protein expression in cell lines derived from hematological malignancies.
| CELL LINE | *pFADD |
|---|---|
| T-cell | |
| FEPD | Nuclei ++ >95% |
| SUDHL-1 | Nuclei + >95% |
| Karpas 299 | Nuclei heterogenous +/++ >50% |
| Jurkat | Nuclei ++ >90% |
| CEM | Nuclei/cytoplasm ++ <50% cells |
| B-cell | |
| SUDHL-6 | Nuclei + >75% |
| SUDHL-10 | Nuclei ++ 90% |
| RIVA | Nuclei + 20% |
| HLY-1 | Nuclei +/− 80% |
| HBL-1 | Nuclei + 40% |
| Thiel | Nuclei +/− 1% |
| Myeloid/megakaryotic | |
| K562 | Nuclei/cytoplasm ++ <95% |
| HL60 | Nuclei/cytoplasm ++ <95% |
| U937 | Nuclei/cytoplasm ++ <95% |
| HEL | Nuclei/cytoplasm ++ <95% |
Notes:
*
Cytoplasmic and nuclear intensity of labeling is as follows: ++ = strong, + = moderate and +/− = weak, % refers to proportion of cells labeled. FEPD – ALK-negative anaplastic large cell lymphoma; SUDHL-1 and Karpas 299 – ALK-positive anaplastic large cell lymphoma; Jurkat and CEM – T-acute lymphoblastic leukemia; SUDHL-6 and SUDHL-10 – germinal center-derived diffuse large B-cell lymphoma; RIVA and HBL-1 – non-germinal center-derived diffuse large B-cell lymphoma; Thiel – myeloma; K562 – chronic myeloid leukemia; U937 and HL60 – acute myeloid leukemia; HEL – megakaryocytic-derived cell lines.